Loading...

BELLUS Health Inc.

BLU.TO•TSX
Healthcare
Biotechnology
CA$19.48
CA$-0.02(-0.10%)

BELLUS Health Inc. (BLU.TO) Company Profile & Overview

Explore BELLUS Health Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

BELLUS Health Inc. (BLU.TO) Company Profile & Overview

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

SectorHealthcare
IndustryBiotechnology
CEORoberto Francesco Bellini

Contact Information

https://www.bellushealth.com
14506804500
275 Armand-Frappier Boulevard, Laval, QC, H7V 4A7

Company Facts

74 Employees
IPO DateJun 22, 2000
CountryCA

Frequently Asked Questions

;